SCHEMBL372402

SCHEMBL372402

NC1CCC2(CC1)OCCO2

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
ALDH1A1 P00352 2/20 0.31
HPGD P15428 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31095712 0.97 LMNA (0.31) LMNAMAPK1ALDH1A1HPGDL3MBTL1
SCHEMBL10893950 0.90
SCHEMBL18610919 0.84
SCHEMBL11820421 0.81
SCHEMBL15326795 0.75
SCHEMBL11816666 0.74 ALDH1A1 (0.30) ALDH1A1
SCHEMBL24424198 0.72
SCHEMBL2631205 0.72
SCHEMBL662249 0.72
SCHEMBL24340232 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4674846-A1 UREA MOTIF CONTAINING COMPOUNDS AS ANTIBACTERIAL DRUGS AGAINST MULTIRESISTANT MYCOBACTERIA Technische Universität München (DE) 2026-01-07 EP claimed
EP-1742925-B1 SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS GRUENENTHAL GMBH (DE) 2014-04-23 EP claimed
EP-1542981-B1 PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINOBENZOTHIAZOLES FROM CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES GENERICS UK LTD (GB) 2009-07-22 EP claimed
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2007-10-25 US claimed
EP-1444206-B1 SUBSTITUTED BENZO[B]AZEPIN-2-ONE COMPOUNDS AS ANALGESICS GRUENENTHAL GMBH (DE) 2006-03-15 EP claimed
EP-1542981-A1 PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINOBENZOTHIAOLES FROM CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES Generics (UK) Limited (GB) 2005-06-22 EP claimed
JP-2005511570-A 2005-04-28 JP claimed
JP-2005511566-A 2005-04-28 JP claimed
EP-1472221-A2 SUBSTITUTED INDOLES, METHOD FOR PRODUCTION AND USE THEREOF FOR THE INHIBITION OF PAIN Grünenthal GmbH (DE) 2004-11-03 EP claimed
EP-1444212-A1 SUBSTITUTED (1H)-QUINOXALIN-2-ONE COMPOUNDS AND SUBSTITUTED 4-ARYL- AND 4-HETEROARYLCYCLOHEXANE COMPOUNDS Grünenthal GmbH (DE) 2004-08-11 EP claimed
EP-1444206-A1 SUBSTITUTED BENZO B AZEPIN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2004-08-11 EP claimed
EP-1442021-A1 SUBSTITUTED 1H-QUINOLIN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2004-08-04 EP claimed
WO-2004026850-A1 PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINOBENZOTHIAOLES FROM CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES GENERICS [UK] LIMITED (GB) 2004-04-01 WO claimed
WO-2003037870-A1 SUBSTITUTED 1H-QUINOLIN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2003-05-08 WO claimed
WO-2003037873-A1 SUBSTITUTED BENZO[B]AZEPIN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2003-05-08 WO claimed
WO-2003037863-A2 SUBSTITUTED INDOLES, METHOD FOR PRODUCTION AND USE THEREOF FOR THE INHIBITION OF PAIN Grünenthal GmbH (DE) 2003-05-08 WO claimed
WO-2003037879-A1 SUBSTITUTED (1H)-QUINOXALIN-2-ONE COMPOUNDS AND SUBSTITUTED 4-ARYL- AND 4-HETEROARYLCYCLOHEXANE COMPOUNDS Grünenthal GmbH (DE) 2003-05-08 WO claimed
US-4652559-A ANALGESIC, ANTIDEPRESSANT THE UPJOHN COMPANY (US) 1987-03-24 US claimed
EP-0085811-B1 2-(PHENYLMETHYLENE)CYCLOALKYLAMINES THE UPJOHN COMPANY (US) 1986-05-07 EP claimed
EP-0085811-A1 2-(Phenylmethylene)cycloalkylamines THE UPJOHN COMPANY (US) 1983-08-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds P2RX7, CYP2C8, P2RX5 LMNA 3096/4885MAPK1 3297/4885ALDH1A1 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.